A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)
Recent evidence has shown that kidney volume predicts the likelihood of developing renal insufficiency over a finite length of time in ADPKD, suggesting a linkage between the growth of cysts and the harm they do to kidney function. Recent studies indicate that the rate of kidney volume increase is hastened by excess dietary protein, salt, and potential net acid precursors, and slowed by increased water intake sufficient to lower plasma vasopressin levels.
Diets are commonly prescribed to treat ADPKD and other renal patients with disease near the end-stage, but there is currently no specific diet prescription that takes potentially harmful dietary elements into account for ADPKD patients in the earliest stages of the disease. This study will examine a novel diet for ADPKD created by the researcher termed the ADPKD diet.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)|
- ADPKD diet impact on net acid excretion [ Time Frame: Change from Baseline to Day 36 ] [ Designated as safety issue: No ]The difference in net acid excretion from a participants regular diet and the ADPKD diet
- Acceptance of ADPKD diet [ Time Frame: 36 days ] [ Designated as safety issue: No ]Ease with which diet will be embraced by participants
- Kidney injury markers [ Time Frame: Change from Baseline to Day 36 ] [ Designated as safety issue: No ]Change in urine markers of renal injury in participants
|Study Start Date:||February 2013|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||February 2015 (Final data collection date for primary outcome measure)|
Experimental: ADPKD Diet
All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
Other: ADPKD Diet
Diet specifically designed for people with ADPKD
Please refer to this study by its ClinicalTrials.gov identifier: NCT01810614
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|Principal Investigator:||Franz Winklhofer, MD||University of Kansas|